Palantir Issues Additional Details About Life Sciences Capabilities to be Shown at “Double Click” on Wednesday, April 14, 2021
DENVER–(BUSINESS WIRE)–Palantir Technologies (NYSE:PLTR) today issued additional details about the Palantir Foundry capabilities it will be highlighting in its Life Sciences demo at “Double Click” on Wednesday, April 14, 2021, at 11:00am ET.
Palantir’s customers in Life Sciences span pharmaceuticals, research institutions, healthcare systems, and others. These customers rely on Foundry’s secure and collaborative architecture to discover and develop drugs, manage commercial launches, conduct clinical research, and distribute vaccines. For example:
- More than 1,000 researchers at the NIH’s National COVID Cohort Collaborative (N3C) use Foundry to securely maintain one of the largest patient-level data assets of COVID-19 Electronic Health Record (EHR) data in the world and collaborate on more than 150 research projects (as illustrated in this video demonstration by N3C).
- Thousands of General Practitioners at NHS England order, allocate, track, and deliver every one of the 29+ million vaccines administered in the country to date (as outlined in the UK Government’s website for data and insights on COVID-19).
At the first installment of Palantir’s Double Click series, engineers will demo the latest Foundry capabilities, as well as several new Archetypes available on top of Foundry that make this work possible in a matter of clicks, including:
- Reproducible research in any environment. Foundry’s interoperable, modular, and open architecture enables users of varying technical ability to integrate any data, use any tool, manage any model, and write code in any language — while maintaining end-to-end reproducibility, transparency, and security of their analyses. Foundry integrates its governance and knowledge management capabilities with common data science environments such as RStudio or HPC clusters, enabling users to work reproducibly with any libraries of their choice — from specialized bioinformatics tools such as plink to machine learning libraries such as scikit-learn, tensorflow, or MLlib.
- Purpose-based access controls. Foundry’s Purpose-Based Access Controls Archetype enables automated or managed assignment of permissions based on the proposed use of a particular data source or dataset. By systematically encoding data access requests alongside the context of the associated research, these access controls provide governance administrators with granular insight into every analysis a piece of data is used for, by whom, and for what reason.
- Systematic model management. Foundry’s Model Management Archetype supports the governance and deployment of predictive models, including those developed outside Foundry. Researchers can readily reproduce results, track how each version of a model was developed, automatically update models when upstream source data changes, compare performance metrics, and tag versions for release into staging or production environments. Models can be deployed within Foundry (batch or streaming, or API endpoint for ad-hoc querying) or to external systems, including specialized hardware. Health checks, telemetry, and rich model monitoring of deployments help organizations go beyond model drift to understand and manage their models against real-world scenarios.
- Out of the box pipeline templates for standardized data models. Foundry’s Pipeline Archetype deploys pre-built data pipelines that convert common real-world data sources such as Optum claims or TriNetX into standard data models, such as OMOP. This enables researchers to easily pivot between sources, and reuse cohort code lists or analytic methods that have already been defined by the open-source community. For unique data sources, such as historic Randomized Controlled Trials, Foundry’s machine learning-powered Entity Resolution Archetype provides the framework for automatically suggesting mappings to a user-defined data model and enabling human-driven confirmation.
For examples of research studies and publications powered by Palantir Foundry, please see the list below.
About Palantir Double Click
Palantir software is used by customers across 40 industries worldwide. Double Click is Palantir’s series of software demo events that showcase how the company’s platforms are used across these industries and customers.
Advance registration is required, and is available at https://palantir.events/doubleclick. Capacity is limited, and registration will close 24 hours prior to the event. For more information regarding the event, please visit https://www.palantir.com/double-click or email email@example.com.
About Palantir Technologies Inc.
Palantir Technologies Inc. builds and deploys operating systems for the modern enterprise. Additional information is available at https://www.palantir.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the event and the expected performance and benefits of, or anticipated updates to, its software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to, our ability to meet the unique or anticipated needs of our customers; the failure of our platforms to satisfy our customers or perform as desired; the frequency or severity of any software and implementation errors; and our platforms’ reliability. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
Third-Party Websites and References
This press release contains links to third party websites or information, which are provided for informational purposes only and are not incorporated by reference herein. You are solely responsible for your own assessment of such information and we make no representations as to their accuracy or completeness nor do we undertake to verify or update any such information. The inclusion of third party links does not constitute endorsement by us of the linked websites or any information or other linked information contained therein.
All third-party products, publications, and names referenced herein are the property of their respective owners. Use of such references is for identification purposes only and does not imply any affiliation with or endorsement by such third-parties.
Select Publications Powered by Palantir Foundry
- Shallcross et al., 2021. Factors associated with SARS-CoV-2 infection and outbreaks in long-term care facilities in England: a national cross-sectional survey. The Lancet Healthy Longevity.
- Dorjsuren et al., 2021. Chemoprotective antimalarials identified through quantitative high-throughput screening of Plasmodium blood and liver stage parasites. Scientific Reports.
- Haendel et al., 2020. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. JAMIA.
- Vellanki et al., 2020. Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs). ASCO 2020.
- Weinstock et al., 2020. Impact of timing of antibiotic use on clinical outcomes in patients with urothelial cancer treated with immune checkpoint inhibitors (ICIs). ASCO 2020.
- Gao et al., 2019. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. The Lancet Oncology.
- Mitchell et al., 2019. Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma in African Americans. Nature Communications.